NASDAQ:SCYX

SCYNEXIS (SCYX) Stock Forecast, Price & News

$2.28

-0.02 (-0.87%)

(As of 09/29/2023 08:53 PM ET)

Compare

Today's Range: $2.25
▼
$2.47
50-Day Range: $1.93
▼
$3.65
52-Week Range: $1.15
▼
$3.87

Volume: 354,900 shs
Average Volume: 839,075 shs
Market Capitalization: $84.77 million

P/E Ratio: 2.71
Dividend Yield: N/A
Price Target: $11.40

SCYNEXIS MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 400.0% Upside
$11.40 Price Target
Short Interest: Healthy
3.66% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.38
Based on 19 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: -91.32%
From $2.65 to $0.23 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

426th out of 968 stocks

Pharmaceutical Preparations Industry

185th out of 450 stocks

3.5

Analyst's Opinion

Consensus Rating
SCYNEXIS has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.40, SCYNEXIS has a forecasted upside of 400.0% from its current price of $2.28.
Amount of Analyst Coverage
SCYNEXIS has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.66% of the outstanding shares of SCYNEXIS have been sold short.
Short Interest Ratio / Days to Cover
SCYNEXIS has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in SCYNEXIS has recently increased by 2.26%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
SCYNEXIS does not currently pay a dividend.
Dividend Growth
SCYNEXIS does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SCYX.

3.0

News and Social Media Coverage

News Sentiment
SCYNEXIS has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 19 news articles for SCYNEXIS this week, compared to 1 article on an average week.
Search Interest
10 people have searched for SCYX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
14 people have added SCYNEXIS to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, SCYNEXIS insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.40% of the stock of SCYNEXIS is held by insiders.
Percentage Held by Institutions
49.87% of the stock of SCYNEXIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for SCYNEXIS are expected to decrease by -91.32% in the coming year, from $2.65 to $0.23 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of SCYNEXIS is 2.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 110.66.
Price to Earnings Ratio vs. Sector
The P/E ratio of SCYNEXIS is 2.71, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 101.16.
Price to Book Value per Share Ratio
SCYNEXIS has a P/B Ratio of 22.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About SCYNEXIS (NASDAQ:SCYX) Stock

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

SCYX Price History

30 days | 90 days | 365 days | Advanced Chart

SCYX Stock News Headlines

September 29, 2023 | tmcnet.com

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Scynexis, Inc. (SCYX)

September 28, 2023 | businesswire.com

SCYNEXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating SCYNEXIS, Inc. on Behalf of Scynexis Stockholders and Encourages Investors to Contact the Firm

October 2, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

September 28, 2023 | tmcnet.com

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Scynexis, Inc. (SCYX) on Behalf of Investors

September 28, 2023 | barrons.com

SCYNEXIS, Inc. (SCYX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

September 27, 2023 | stockhouse.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX

September 27, 2023 | benzinga.com

The Law Offices of Frank R. Cruz Continues Investigation of Scynexis, Inc. (SCYX) on Behalf of Investors

September 26, 2023 | msn.com

Scynexis: From Fungal To Bungle, The Brexafemme Recall And A Slippery Slope (Rating Downgrade)

October 2, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

September 26, 2023 | markets.businessinsider.com

Scynexis Recalls GSK- Licensed Ibrexafungerp Tablets, Halts Trials On Contamination Concerns

September 26, 2023 | americanbankingnews.com

Head-To-Head Review: SCYNEXIS (NASDAQ:SCYX) & Alkermes (NASDAQ:ALKS)

September 25, 2023 | benzinga.com

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Scynexis, Inc. (SCYX) on Behalf of Investors

September 25, 2023 | markets.businessinsider.com

Nasdaq Turns Higher; SCYNEXIS Shares Plunge

September 25, 2023 | tmcnet.com

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Scynexis, Inc. (SCYX) on Behalf of Investors

September 25, 2023 | benzinga.com

The Law Offices of Frank R. Cruz Announces Investigation of Scynexis, Inc. (SCYX) on Behalf of Investors

September 25, 2023 | msn.com

Why Are Antifungal Focused Scynexis Stock Plunging Today?

September 25, 2023 | marketwatch.com

Scynexis Shares Fall More Than 30% After Brexafemme Recall >SCYX

September 25, 2023 | reuters.com

Scynexis to recall antifungal from market, pause studies

September 25, 2023 | marketwatch.com

Scynexis Shares Slide Premarket on Brexafemme Recall, Study Hold >SCYX

September 12, 2023 | finance.yahoo.com

SCYNEXIS, Inc.'s (NASDAQ:SCYX) Stock Is Going Strong: Have Financials A Role To Play?

September 4, 2023 | finance.yahoo.com

SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why

August 28, 2023 | finance.yahoo.com

SCYNEXIS to Participate in September Investor Conferences

August 16, 2023 | markets.businessinsider.com

SCYNEXIS (SCYX) Receives a Buy from Maxim Group

August 16, 2023 | finance.yahoo.com

Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues

August 15, 2023 | finanznachrichten.de

Scynexis: SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 15, 2023 | msn.com

Cantor Fitzgerald Reiterates Scynexis (SCYX) Overweight Recommendation

August 14, 2023 | seekingalpha.com

SCYNEXIS GAAP EPS of $2.46 beats by $1.01, revenue of $131.5M beats by $36.1M

See More Headlines

Receive SCYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter.

SCYX Company Calendar

Last Earnings: 8/14/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SCYX
CUSIP: N/A
CIK: 1178253
Web: www.scynexis.com
Phone: (201) 884-5485
Fax: 201-884-5490
Employees: 36
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $11.40
High Stock Price Forecast: $15.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +400.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.84
Trailing P/E Ratio: 2.71
Forward P/E Ratio: 0.86
P/E Growth: N/A
Net Income: $-62,810,000.00
Net Margins: 32.71%
Pretax Margin: 32.71%
Return on Equity: 317.92%
Return on Assets: 62.50%

Debt

Debt-to-Equity Ratio: 0.12
Current Ratio: 9.01
Quick Ratio: 8.37

Sales & Book Value

Annual Sales: $5.09 million
Price / Sales: 16.65
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.10 per share
Price / Book: 22.80

Miscellaneous

Outstanding Shares: 37,180,000
Free Float: 35,540,000
Market Cap: $84.77 million
Optionable: Optionable
Beta: 2.14

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. David Gonzalez Angulo M.D. (Age 58)
CEO, Pres & Director
Comp: $631.69k

Mr. Scott Sukenick J.D. (Age 45)
Chief Legal Officer & Corp. Sec.
Comp: $542.05k

Mr. Ivor Macleod CPA (Age 62)
M.B.A., Chief Financial Officer

Debbie Etchison
Exec. Director of Communications

Ms. Daniella Gigante
VP of HR & Information Technology

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SCYX Stock - Frequently Asked Questions

Should I buy or sell SCYNEXIS stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SCYX shares.
View SCYX analyst ratings or view top-rated stocks.
What is SCYNEXIS's stock price forecast for 2023?: 4 brokers have issued 1-year target prices for SCYNEXIS's shares. Their SCYX share price forecasts range from $8.00 to $15.00. On average, they predict the company's stock price to reach $11.40 in the next year. This suggests a possible upside of 400.0% from the stock's current price.
View analysts price targets for SCYX or view top-rated stocks among Wall Street analysts.
How have SCYX shares performed in 2023?: SCYNEXIS's stock was trading at $1.56 on January 1st, 2023. Since then, SCYX shares have increased by 46.2% and is now trading at $2.28.
View the best growth stocks for 2023 here.
When is SCYNEXIS's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our SCYX earnings forecast.
How were SCYNEXIS's earnings last quarter?: SCYNEXIS, Inc. (NASDAQ:SCYX) issued its quarterly earnings data on Monday, August, 14th. The company reported $2.46 EPS for the quarter, topping analysts' consensus estimates of $1.03 by $1.43. The business earned $131.45 million during the quarter, compared to the consensus estimate of $91.50 million. SCYNEXIS had a trailing twelve-month return on equity of 317.92% and a net margin of 32.71%.
When did SCYNEXIS's stock split?: SCYNEXIS's stock reverse split before market open on Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of SCYNEXIS own?: Based on aggregate information from My MarketBeat watchlists, some companies that other SCYNEXIS investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Sorrento Therapeutics (SRNE), Gran Tierra Energy (GTE), KushCo (KSHB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Outlook Therapeutics (OTLK), Cogent Biosciences (UMRX) and Aeterna Zentaris (AEZS).
What is SCYNEXIS's stock symbol?: SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."
How do I buy shares of SCYNEXIS?: Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is SCYNEXIS's stock price today?: One share of SCYX stock can currently be purchased for approximately $2.28.
How much money does SCYNEXIS make?: SCYNEXIS (NASDAQ:SCYX) has a market capitalization of $84.77 million and generates $5.09 million in revenue each year. The company earns $-62,810,000.00 in net income (profit) each year or $0.84 on an earnings per share basis.
How can I contact SCYNEXIS?: SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The official website for the company is www.scynexis.com. The company can be reached via phone at (201) 884-5485, via email at ikoffler@lifesciadvisors.com, or via fax at 201-884-5490.

This page (NASDAQ:SCYX) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial